Detalhe da pesquisa
1.
Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.
Br J Clin Pharmacol
; 76(1): 65-77, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23278647
2.
A Colon-Targeted Adsorbent (DAV132) Does Not Affect the Pharmacokinetics of Warfarin or Clonazepam in Healthy Subjects.
Clin Pharmacol Drug Dev
; 10(8): 908-917, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33434399
3.
Tolerability, safety, and pharmacokinetics of the novel cathepsin A inhibitor SAR164653 in healthy subjects.
Clin Pharmacol Drug Dev
; 5(1): 57-68, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27119579
4.
Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
J Am Heart Assoc
; 5(6)2016 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27287699
5.
Pharmacokinetics and safety of a single oral dose of once-daily alfuzosin, 10 mg, in male subjects with mild to severe renal impairment.
J Clin Pharmacol
; 42(12): 1311-7, 2002 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-12463725
6.
Mapping the cerebral monoamine oxidase type A: positron emission tomography characterization of the reversible selective inhibitor [11C]befloxatone.
J Pharmacol Exp Ther
; 305(2): 467-73, 2003 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-12606609
7.
Synthesis and in vivo imaging properties of [11C]befloxatone: a novel highly potent positron emission tomography ligand for mono-amine oxidase-A.
Bioorg Med Chem Lett
; 13(10): 1771-5, 2003 May 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-12729662